Greg Chopskie has extensive experience as in-house counsel to several multibillion-dollar publicly traded life sciences companies. He offers an insider’s knowledge to the development of effective legal strategies and tactics in both domestic and international IP disputes, with a unique capability in and familiarity with Hatch-Waxman litigation. His skillset includes IP portfolio design, due diligence, international commercial transactions, and international competition matters. He is a strategic counselor in all phases of international disputes relating to complex IP portfolios, helping clients ensure company value is preserved and enhanced.
Prior to joining the firm, Greg was a partner at a global law firm, as well as an associate general counsel for intellectual property at Gilead Sciences, where he directed IP litigation in the US and overseas. Prior to that, he served in senior in-house counsel positions at Wyeth, Shionogi, and Pfizer.
During his time as in-house counsel, he led several groundbreaking initiatives to streamline legal services delivery, ameliorate complex global risks and seize commercial opportunity. Examples of this work include:
He is frequently acknowledged for his capabilities, including a recommendation from The Legal 500 US in 2017 for Patent Litigation. He was also named a Corporate IP Star in 2016 by Managing Intellectual Property.